Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

DANISH MEDICAL DEVICES CONSULTING ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9%   Bankruptcy risk   4.7% 2.5% 3.0% 2.0% 2.5% 3.4% 14.2% 14.2%   Credit score (0-100)   47 62 56 68 61 54 15 15   Credit rating   BBB BBB BBB A BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   2,470 1,782 1,993 1,488 1,640 1,893 0.0 0.0   EBITDA   1,813 848 1,017 704 790 954 0.0 0.0   EBIT   1,813 848 1,017 704 790 954 0.0 0.0   Pre-tax profit (PTP)   1,812.8 844.6 1,012.8 699.9 790.3 953.7 0.0 0.0   Net earnings   1,412.3 653.6 784.3 313.4 612.7 967.1 0.0 0.0   Pre-tax profit without non-rec. items   1,813 845 1,013 700 790 954 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   1,011 240 874 487 600 1,067 387 387   Interest-bearing liabilities   12.4 271 0.5 97.0 199 159 0.0 0.0   Balance sheet total (assets)   1,688 1,201 1,458 971 1,205 1,441 387 387   Net Debt   -1,197 -407 -269 -62.1 13.4 -158 -387 -387     See the entire balance sheet 1000.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   2,470 1,782 1,993 1,488 1,640 1,893 0.0 0.0   Gross profit growth   285.9% -27.9% 11.9% -25.3% 10.2% 15.5% -100.0% 0.0%   Employees   0 2 2 2 2 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,688 1,201 1,458 971 1,205 1,441 387 387   Balance sheet change%   17.0% -28.9% 21.4% -33.4% 24.1% 19.6% -73.1% 0.0%   Added value   1,813.1 848.0 1,016.5 703.6 790.3 953.7 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   73.4% 47.6% 51.0% 47.3% 48.2% 50.4% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   115.8% 58.7% 76.5% 57.9% 72.6% 72.1% 0.0% 0.0%   ROI %   230.5% 110.6% 146.8% 96.4% 114.3% 94.2% 0.0% 0.0%   ROE %   181.0% 104.5% 140.8% 46.0% 112.7% 116.0% 0.0% 0.0%   1000.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   59.9% 20.0% 60.0% 50.2% 49.8% 74.1% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -66.0% -48.0% -26.5% -8.8% 1.7% -16.6% 0.0% 0.0%   Gearing %   1.2% 112.8% 0.1% 19.9% 33.1% 14.9% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   6.1% 2.4% 2.7% 7.7% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   4.0 1.6 4.1 2.0 2.8 9.1 0.0 0.0   Current Ratio   4.0 1.6 4.1 2.0 2.8 9.1 0.0 0.0   Cash and cash equivalent   1,209.8 677.9 269.8 159.1 185.2 317.3 0.0 0.0   1000.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,267.5 430.9 1,102.7 487.5 777.8 1,282.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 424 508 352 395 477 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 424 508 352 395 477 0 0   EBIT / employee   0 424 508 352 395 477 0 0   Net earnings / employee   0 327 392 157 306 484 0 0